National Drug Service Organisation Pharmaceutical Import Profile — Lesotho (DGFT 2022–2026)

Name: National Drug Service Organisation Pharmaceutical Import Records from India — 3 Products, $650.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

National Drug Service Organisation — Pharmaceutical Importer Profile (2026) | 3 Products, $650.0K Trade | TransData Nexus

National Drug Service Organisation

Pharmaceutical Importer · Lesotho · Tuberculosis Medications Focus · $650.0K Total Trade · DGFT Verified

National Drug Service Organisation is a pharmaceutical importer based in Lesotho with a total trade value of $650.0K across 3 products in 2 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. National Drug Service Organisation sources from 10 verified Indian suppliers, with Coral Laboratories Limited accounting for 31.7% of imports.

National Drug Service Organisation — Import Portfolio & Supplier Network

National Drug Service Organisation import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to National Drug Service Organisation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Coral Laboratories Limited	$510.4K	101	31.7%
Micro Labs Limited	$382.7K	29	23.7%
Macleods Pharmaceuticals Limited	$176.9K

What Formulations Does National Drug Service Organisation Import?

Formulation	Value	Ships
Indocor suppositories- (contains	$55.7K	5
Coral`s amitriptyline tablets-	$50.1K	3
Metformin tablets BP 850 MG (10 x 10's	$50.0K	1
Medicines dolutegravir sodium 10MG tablets net 10 5300 kgs dolutegravir	$50.0K	1
Rifampicin 150MG / isoniazid 75MG/	$50.0K	1
Lamivudine & tenofovir tablets lamivuine 300MG+tenofovir disoproxil fumarate 300MG - 25524 pacx30 tabs	$50.0K	1
Rifampicin 150MG / isoniazid 75MG / ethambutol hydrochloride 275MG tablets bno:nra2301a md.09/23 ed.08/26 ps: 24x28s	$50.0K	1
Megatrim ds cotrimoxazole tablets BP	$47.5K	2
Metformin tablets BP 500 MG 10x10 s qty 68940	$44.6K	1
Doxycycline hyclate tablets USP 100MG	$41.3K	1
Hydrochlorothiazide tablets BP 25MG (100000 x 10 x 10) -	$40.5K	1
Isoniazid tablets BP 300	$39.1K	1
Coremycin suspension - (contains	$37.2K	10
Metformin tablets BP 850 MG	$35.2K	1
Doxycycline tablets BP 100MG(19990 x 10x10)-	$33.6K	1

National Drug Service Organisation imports 272 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$350.0K	7	0.0%	13
2	Rifampicin	Advanced Antibiotics	$200.0K	4	0.0%	9
3	Ethambutol	Tuberculosis Medications	$100.0K	2	0.0%	8

National Drug Service Organisation imports 3 pharmaceutical products across 2 categories into Lesotho totaling $650.0K.

National Drug Service Organisation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The National Drug Service Organisation (NDSO) is the central medical store for the Ministry of Health in Lesotho, responsible for the procurement, storage, and distribution of medicines and medical consumables to health institutions nationwide. Established as a trading account through a legal notice on 2nd March 2007, NDSO operates as a non-profit entity, recovering its costs through a handling fee system. (ndso.org.ls) Headquartered in Mafeteng, Lesotho, NDSO serves as the primary wholesaler and distributor of pharmaceuticals and medical equipment in the country, ensuring the availability of safe, effective, and affordable medicines in both public and private sectors. (ndso.org.ls)

2Distribution Network

NDSO's distribution network is centralized at its main facility in Mafeteng, Lesotho. The organization operates high-standard storage facilities, comparable to those of leading pharmaceutical manufacturers and distributors globally, to ensure the quality and safety of its products. (ndso.org.ls) While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, NDSO's centralized operations suggest a focus on efficient distribution within Lesotho.

3Industry Role

As the central medical store for the Ministry of Health, NDSO plays a pivotal role in Lesotho's pharmaceutical supply chain. It functions as the primary wholesaler and distributor, sourcing medicines and medical consumables from accredited suppliers and ensuring their availability to health facilities across the country. By managing the procurement, storage, and distribution processes, NDSO ensures that both public and private health institutions have access to essential medical products. (ndso.org.ls)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — National Drug Service Organisation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NDSO's sourcing strategy exhibits a high degree of concentration, with a total import value of $650,000 USD from India across 13 shipments, importing 272 unique formulations. The top five products—isoniazid, rifampicin, ethambutol, and two other unspecified products—account for 100% of the import value, indicating a focused procurement approach. This concentration suggests a strategic choice to streamline operations and maintain consistent product quality. However, such dependency on a limited number of suppliers and products may pose risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

NDSO's supply chain resilience is closely tied to its sourcing strategy. The organization's reliance on a concentrated supplier base, particularly from India, may expose it to risks associated with geopolitical tensions, regulatory changes, or logistical challenges affecting this region. While NDSO's high-standard storage facilities mitigate some risks, the lack of publicly available information on backup suppliers and alternative sourcing strategies suggests potential vulnerabilities in the supply chain. Ensuring compliance with international Good Manufacturing Practice (GMP) standards among suppliers is crucial for maintaining product quality and safety.

Strategic Implications

Importing Pharmaceuticals into Lesotho — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Lesotho

1Regulatory Authority & Framework

The Lesotho Medicines and Medical Devices Control Authority (LMMDCA) is the primary regulatory body overseeing the manufacture, import, export, storage, distribution, sale, and use of medicines and medical devices in Lesotho. Established under the Medicine Control Bill 2022, the LMMDCA is responsible for ensuring that medical products circulating in the country are of good quality, efficacy, and safe use. (nationalassembly.parliament.ls) The Bill outlines the functions of the Authority, including regulating the pharmaceutical industry and performing other related functions as directed by its Board. The Board comprises members appointed by the Minister, including the Head of Pharmaceutical Services in the Ministry of Health and other experts in the field.

2Import Licensing & GMP

Importers of pharmaceutical products into Lesotho must obtain the necessary import licenses from the LMMDCA, ensuring compliance with national regulations. The Medicine Control Bill 2022 stipulates that no person shall import, export, or bring to Lesotho in transit a drug of abuse, controlled chemical, equipment, or material without obtaining a separate import/export or transit permit for each transaction. (nationalassembly.parliament.ls) Additionally, importers are required to source products from suppliers with relevant GMP accreditation, such as EU GMP, WHO GMP, or PIC/S, to ensure product quality and safety. Wholesale distribution authorization is also mandatory for entities involved in the distribution of medical products within Lesotho.

National Drug Service Organisation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

NDSO's focus on importing tuberculosis medications, including isoniazid, rifampicin, and ethambutol, aligns with the high prevalence of tuberculosis in Lesotho. The country's healthcare system prioritizes the treatment and management of this infectious disease, necessitating a consistent and reliable supply of these essential medicines. The importation of advanced antibiotics further supports the treatment of various bacterial infections, addressing critical healthcare needs. This strategic product focus ensures that NDSO meets the therapeutic demands of the population, contributing to improved health outcomes.

2Sourcing Profile

NDSO's sourcing strategy is centered on procuring generic drug formulations from suppliers with relevant GMP accreditation, primarily from India. This approach ensures access to cost-effective medicines without compromising on quality. The organization's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-use products that meet the immediate needs of healthcare providers. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for NDSO's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to National Drug Service Organisation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with NDSO, given the organization's focus on sourcing generic drug formulations from suppliers with relevant GMP accreditation. Suppliers can explore opportunities by ensuring compliance with Lesotho's regulatory requirements and demonstrating the quality and efficacy of their products. Identifying gaps in NDSO's current sourcing, such as the need for additional therapeutic categories or specialized formulations, can provide avenues for new suppliers to introduce their products. Building relationships with NDSO through transparent communication and adherence to quality standards will be crucial for successful collaboration.

2Requirements & Qualifications

Indian exporters seeking to supply NDSO and the Lesotho market must ensure that their products are manufactured in facilities with relevant GMP accreditation, such as EU GMP, WHO GMP, or PIC/S. Compliance with Lesotho's import licensing requirements, including obtaining the necessary permits for each transaction involving controlled substances, is mandatory. Additionally, adherence to Lesotho's quality and labeling standards, including batch testing, stability requirements, and appropriate labeling, is essential. Exporters should also be prepared to provide documentation and certifications that verify the quality and safety of their products.

Frequently Asked Questions — National Drug Service Organisation

What products does National Drug Service Organisation import from India?

National Drug Service Organisation imports 3 pharmaceutical products across 2 categories. Top imports: Isoniazid ($350.0K), Rifampicin ($200.0K), Ethambutol ($100.0K).

Who supplies pharmaceuticals to National Drug Service Organisation from India?

National Drug Service Organisation sources from 10 verified Indian suppliers. The primary supplier is Coral Laboratories Limited (31.7% of imports, $510.4K).

What is National Drug Service Organisation's total pharmaceutical import value?

National Drug Service Organisation's total pharmaceutical import value from India is $650.0K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does National Drug Service Organisation focus on?

National Drug Service Organisation imports across 2 categories. The largest: Tuberculosis Medications (69.2%), Advanced Antibiotics (30.8%).

Get Full National Drug Service Organisation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.